Skip to main content
Clinical Trials/NCT00971074
NCT00971074
Withdrawn
Not Applicable

The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy

Grant Jones1 site in 1 countryDecember 2009

Overview

Phase
Not Applicable
Intervention
Hylan G-F 20
Conditions
Arthralgia
Sponsor
Grant Jones
Locations
1
Primary Endpoint
VAS pain scale
Status
Withdrawn
Last Updated
5 years ago

Overview

Brief Summary

The investigators' objective is to analyze a group of patients who have had a partial meniscectomy but continue to have knee pain after surgery with a double-blind, randomized prospective study comparing the use of Hylan G-F 20(single injection of a viscosupplementation) versus placebo injection. The investigators would expect patients who receive the treatment (Hylan G-F 20) to have lower pain compared to the patients who were in the placebo group (had the needle injected into the knee but no medication or substance injected) since Hylan G-F 20 has been shown to decrease pain in arthritic patients.

Detailed Description

A great majority of patients who have a partial menisectomy for mechanical symptoms do well with full return of function without pain. There is a sub-group of patients who are found to have Grade II- III chondromalacia lesions (deemed arthritic) at the time of surgery that have persistent generalized "arthritic-type" pain despite relief of their mechanical symptoms. To date, there are no published studies analyzing if this treatment is better than no treatment in this group of patients. We would expect patients who receive the treatment (Hylan G-F 20) to have lower pain compared to the patients who were in the placebo group (had the needle injected into the knee but no medication or substance injected) since Hylan G-F 20 has been shown to decrease pain in arthritic patients.

Registry
clinicaltrials.gov
Start Date
December 2009
End Date
December 2011
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Grant Jones

Associate Professor-Clinical, Orthopaedics

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Age 18-60
  • S/P partial medial and/or lateral partial meniscectomy
  • Pre-operative MRI diagnosed meniscal tear
  • Diffuse, non-focal arthroscopically diagnosed ICRS Grade II or III chondromalacia. (used to determine the presence of tibiofemoral osteoarthritis)
  • Baseline VAS pain score between 50 and 80mm.
  • Persistent, generalized knee pain without mechanical symptoms
  • Kellgren/Lawrence (K/L) grade II or III (used to determine the presence of tibiofemoral osteoarthritis)

Exclusion Criteria

  • Bilateral arthroscopy (within 6 months pre- and post- initial VAS score.
  • Complete meniscectomy
  • Microfracture (via drilling, picking, abrading, thermal or radiofrequency or any procedure that violates the subchondral plate)
  • Focal chondral lesion visualized on arthroscopy or any focal cartilage procedure (e.g. ACI, OATS, mosaicplasty, etc)
  • Concomitant ligamentous injury or repair
  • K/L stage I or IV
  • Significant Varus or Valgus clinical malalignment
  • S/P tibial osteotomy in target knee
  • Isolated patello-femoral OA or isolated anterior knee pain
  • Prosthetic implant in either knee

Arms & Interventions

Hylan G-F 20

Single injection of Hylan G-F 20 into the affected knee.

Intervention: Hylan G-F 20

Sham Injection

A needle will be inserted through the knee capsule but no medication will be injected.

Intervention: Sham Injection

Outcomes

Primary Outcomes

VAS pain scale

Time Frame: 0, 2, 6, 12, 18, 26 weeks

Secondary Outcomes

  • Knee injury and Osteoarthritis Outcome Score(0, 2, 6, 12, 18, 26 weeks)
  • Physical Examination(0, 2, 6, 12, 18, 26 weeks)
  • SF-36® Health Survey(0, 2, 6, 12, 18, 26 weeks)

Study Sites (1)

Loading locations...

Similar Trials